NCT06596356

A Mass Balance Study of TS-172 in Healthy Adult Subjects

A Phase 1 Mass Balance Study of TS-172 in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Taisho Pharmaceutical Co., Ltd. · Industry
• Sex: Male
• Age: 20 Years – 39 Years
• Healthy volunteers: Accepted

Summary

To assess the plasma pharmacokinetics, the routes extent of elimination, and the metabolites of TS-172 after single oral dose of \[14C\] TS-172 in Japanese healthy male subjects. To assess the safety of single oral dose of \[14C\] TS-172 in Japanese healthy male subjects.

Conditions

• Healthy Male Subjects

Interventions

Type	Name	Description
DRUG	[14C] TS-172	Subjects will receive single dose of about 30 mg of TS-172 containing 1 MBq \[14C\]TS-172 as an oral solution

Timeline

• Start date: 2024-09-26
• Primary completion: 2024-10-28
• Completion: 2024-10-28
• First posted: 2024-09-19
• Last updated: 2025-02-28

Locations

1 site across 1 country: Japan